Skip to content
value.today

Minerva Biotechnologies Corp.

🇺🇸 Waltham, Massachusetts, USABiotechnologyFounded 2006
Total raised
$68 M
6 rounds on record
Latest round
$5 M
Nov 2023
First round on record
Jul 2009
Today
Private
No later event on record

Funding rounds

6 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Minerva Biotechnologies Corp.
MonthRaisedRaiseSizeInvestorsSoldFiling
Nov 2023$5 MNo. 6$2 to $10 million

Minerva Biotechnologies Corp.: Raise no. 6, Nov 2023

Investors in this round

9 investors had bought by the notice of Dec 5, 2023: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $8 M offered; $3 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Cynthia Bamdad · Executive Officer, Director
  • James R. Bridges · Director
  • Joseph Anthony Nathan · Director
  • Kenneth Anthony Reed · Director
  • Kenneth Kosik · Director
  • Lawrence Anthony Coolidge · Director
  • Robert Staszewski · Director
  • Ronald R. Axelrod · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Cynthia Bamdad, President & Chief Executive Officer. Source: SEC Form D, newest notice filed Dec 5, 2023. Read the notice at the SEC.

equitySEC
Oct 2019$24 MNo. 5$10 to $50 million

Minerva Biotechnologies Corp.: Raise no. 5, Oct 2019

Investors in this round

65 investors had bought by the notice of Jan 28, 2022: 65 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$24 M of $30 M offered; $6 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Cynthia Bamdad · Executive Officer, Director · President & Chief Executive Officer
  • James R. Bridges · Director
  • Joseph Anthony Nathan · Director
  • Kenneth Anthony Reed · Director
  • Kenneth Kosik · Director
  • Lawrence Anthony Coolidge · Director
  • Robert Staszewski · Director
  • Ronald R. Axelrod · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Offering is Closed.”

Signed by Cynthia Bamdad, President & Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed Jan 28, 2022. Read the notice at the SEC.

equitySEC
Mar 2019$4 MNo. 4$2 to $10 million

Minerva Biotechnologies Corp.: Raise no. 4, Mar 2019

Investors in this round

9 investors had bought by the notice of Apr 5, 2019: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $12 M offered; $8 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Nevada

People named in the notice

  • Cynthia Bamdad · Executive Officer, Director · President & Chief Executive Officer
  • James F. Bridges · Director
  • Joseph Anthony Nathan · Director
  • Kenneth Anthony Reed · Director
  • Kenneth Kosik · Director
  • Lawrence Anthony Coolidge · Director
  • Normand F. Smith · Director
  • Robert Staszewski · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Cynthia Bamdad, President & Chief Executive Officer. Source: SEC Form D, newest notice filed Apr 5, 2019. Read the notice at the SEC.

equitySEC
Oct 2014$29 MNo. 3$10 to $50 million

Minerva Biotechnologies Corp.: Raise no. 3, Oct 2014

Investors in this round

79 investors had bought by the notice of Oct 2, 2018: 79 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$29 M of $31 M offered; $2 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Nevada

People named in the notice

  • Cynthia Bamdad · Executive Officer, Director · President & Chief Executive Officer
  • James F. Bridges · Director
  • Joseph Anthony Nathan · Director
  • Kenneth Anthony Reed · Director
  • Kenneth Kosik · Director
  • Lawrence Anthony Coolidge · Director
  • Normand F. Smith · Director
  • Robert Staszewski · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Cynthia Bamdad, President & Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed Oct 2, 2018. Read the notice at the SEC.

equitySEC
Nov 2010$5 MNo. 2$2 to $10 million

Minerva Biotechnologies Corp.: Raise no. 2, Nov 2010

Investors in this round

17 investors had bought by the notice of Nov 17, 2010: 17 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $6 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Nevada

People named in the notice

  • Cynthia Bamdad · Executive Officer, Director
  • Kenneth Kosik · Director
  • Kenneth Reed · Director
  • Normand Smith · Director
  • Robert Staszewski · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Not including warrants which could amount for additional $1,130,000.”

Signed by Cynthia Bamdad, President. Source: SEC Form D, newest notice filed Nov 17, 2010. Read the notice at the SEC.

equity, optionsSEC
Jul 2009$2 MNo. 1Under $2 million

Minerva Biotechnologies Corp.: Raise no. 1, Jul 2009

Investors in this round

20 investors had bought by the notice of Feb 23, 2010: 20 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $5 M offered; $3 M still to sell
Smallest investment taken
$50,000
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Nevada

People named in the notice

  • Cynthia Bamdad · Executive Officer, Director, Promoter
  • Kenneth Kosik · Director
  • Kenneth Reed · Director
  • Normand Smith · Director
  • Robert Staszewski · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Cynthia Bamdad, President. Source: SEC Form D, newest notice filed Feb 23, 2010. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Minerva Biotechnologies Corp. chose not to state its revenue in its newest notice of a funding round (Dec 2023).

    SEC Form D · Dec 2023

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Dec 2023

That is all the official record says: Minerva Biotechnologies Corp. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Minerva Biotechnologies Corp. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 6 rounds above had up to 79 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Minerva Biotechnologies Corp.
NameRoleNamed in
Cynthia BamdadExecutive officerDec 2023
Normand S SmithSecretaryOct 2014
Cynthia BamdadDirectorDec 2023
James R. BridgesDirectorDec 2023
Joseph Anthony NathanDirectorDec 2023
Kenneth Anthony ReedDirectorDec 2023
Kenneth KosikDirectorDec 2023
Lawrence Anthony CoolidgeDirectorDec 2023
Robert StaszewskiDirectorDec 2023
Ronald R. AxelrodDirectorDec 2023
James F. BridgesDirectorOct 2019
Normand F. SmithDirectorOct 2019
James S BridgesDirectorOct 2014
Kenneth ReedDirectorOct 2014
Normand S SmithSecretaryOct 2014
Normand SmithDirectorNov 2010
Cynthia BamdadPromoterFeb 2010